Literature DB >> 19931382

Comparability of antibody response to a booster dose of 7-valent pneumococcal conjugate vaccine in infants primed with either 2 or 3 doses.

Gerwin D Rodenburg1, Elske J M van Gils, Reinier H Veenhoven, Nienke Jones, Irina Tcherniaeva, Eelko Hak, Loek van Alphen, Guy A M Berbers, Elisabeth A M Sanders.   

Abstract

In this cohort study we compared IgG antibody levels between infants immunized with 7-valent CRM197-conjugated pneumococcal vaccine (PCV-7) at 2, 4 and 11 months and at 2, 3, 4 and 11 months of age, as measured by double adsorption ELISA. Pre- and post-booster levels following the 2+1- and 3+1-dose schedule were comparable for 5 out of 7 serotypes except for serotypes 6B and 19F. The proportion of children reaching post-booster antibody thresholds were comparable except for 6B (>or=1.0 microg/ml and >or=5.0 microg/ml) and 19F (>or=5.0 microg/ml). Surveillance studies are warranted for vaccine impact on 6B and 19F disease cases after reduced-dose PCV-7 schedules. (c) 2009 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19931382     DOI： 10.1016/j.vaccine.2009.10.151

Source DB:  PubMed          Journal:  Vaccine        ISSN： 0264-410X            Impact factor:   3.641


  5 in total

1.  Nasopharyngeal colonization elicits antibody responses to staphylococcal and pneumococcal proteins that are not associated with a reduced risk of subsequent carriage.

Authors:  Sabine M P J Prevaes; Willem J B van Wamel; Corné P de Vogel; Reinier H Veenhoven; Elske J M van Gils; Alex van Belkum; Elisabeth A M Sanders; Debby Bogaert
Journal:  Infect Immun       Date:  2012-03-26       Impact factor: 3.441

Review 2.  Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on immunogenicity.

Authors:  Maria Deloria Knoll; Daniel E Park; T Scott Johnson; Subash Chandir; Bareng Aletta S Nonyane; Laura Conklin; Katherine E Fleming-Dutra; Jennifer D Loo; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

Review 3.  The differential impact of coadministered vaccines, geographic region, vaccine product and other covariates on pneumococcal conjugate vaccine immunogenicity.

Authors:  Daniel E Park; T Scott Johnson; Bareng Aletta S Nonyane; Subhash Chandir; Laura Conklin; Katherine E Fleming-Dutra; Jennifer D Loo; David Goldblatt; Cynthia G Whitney; Katherine L O'Brien; Maria Deloria Knoll
Journal:  Pediatr Infect Dis J       Date:  2014-01       Impact factor: 2.129

4.  Routine infant immunization with the 7- and 13-valent pneumococcal conjugate vaccines: current perspective on reduced-dosage regimens.

Authors:  Teresa Jackowska; Justyna Pluta
Journal:  Arch Med Sci       Date:  2012-07-04       Impact factor: 3.318

5.  Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.

Authors:  Gerwin D Rodenburg; Elisabeth A M Sanders; Elske J M van Gils; Reinier H Veenhoven; Tomasz Zborowski; Germie P J M van den Dobbelsteen; Andries C Bloem; Guy A M Berbers; Debby Bogaert
Journal:  PLoS One       Date:  2012-10-16       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.